Stable ready to dilute formulations of carfilzomib

HK40137314APending Publication Date: 2026-09-11K I PHARM LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK42026126391
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-12
Filing Date
2026-07-20
Publication Date
2026-09-11
Patent Text Reader

Abstract

The present invention provides room temperature stable, i.e., dilution injectable formulations comprising carfilzomib or a pharmaceutically acceptable derivative thereof. The invention also provides a method of treating a patient suffering from multiple myeloma by administering a room temperature stable, i.e., dilution injectable formulation comprising carfilzomib or a pharmaceutically acceptable derivative thereof.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication No. CN 121465991 A (43) Publication Date Feb. 06, 2026 (21) Application No. 202511431956.1 (22) Filing Date Apr. 15, 2021 (30) Priority Data 202021016383 Apr. 15, 2020 IN 202021049395 Nov. 12, 2020 IN (62) Divisional Original Application Data 202180039555.5 Apr. 15, 2021 (71) Applicant Kashiv Biosciences LLC Address New Jersey, US (51) Int.Cl. A61K 9 / 08(2006.01) A61K 9 / 00(2006.01) A61K 38 / 08(2019.01) A61K 47 / 10(2017.01) A61K 47 / 18(2017.01) A61K 47 / 22(2006.01) A61K 47 / 20(2006.01) A61K 47 / 14(2017.01) A61P 35 / 00(2006.01) (72) Inventor Parash Ratilal Dhanak Sandeep Pareshbhai Mehta (74) Patent Agency Beijing Xinhui Yongguang Intellectual Property Agency Co., Ltd. 11290 Patent Attorneys Sun Xue Yang Guoqiang 2 pages of claims, 30 pages of description (54) Title of the Invention Stable ready-to-dilute formulation of carfilzomib (57) Abstract The present invention provides a room temperature stable ready-to-dilute injectable formulation comprising carfilzomib or a pharmaceutically acceptable derivative thereof. The present invention also provides a method for treating a patient suffering from multiple myeloma by administering the room temperature stable ready-to-dilute injectable formulation comprising carfilzomib or a pharmaceutically acceptable derivative thereof. V I 6 6 S T 4 - § CN 121465991 A Claims 1 / 2 Page 1. A room temperature stable ready-to-dilute injectable formulation, comprising carfilzomib or a pharmaceutically acceptable derivative thereof and one or more solvents, wherein the solvent is selected from the group consisting of isopropyl alcohol, N-methyl-2-pyrrolidone, dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide (DMSO), diethylene glycol monoethyl ether, caprylocaproyl polyoxylglycerides, tetrahydrofuran polyethylene glycol ether, and a mixture thereof, wherein the formulation has no more than 6% of total impurities after storage for at least three months. 2. The room temperature stable ready-to-dilute injectable formulation according to claim 1, wherein the concentration of carfilzomib or the pharmaceutically acceptable derivative thereof ranges from about 10 mg / mL to about 100 mg / mL. 3.The room-temperature stable, dilution-type injectable formulation according to claim 1 or 2, wherein the concentration of carfilzomib or a pharmaceutically acceptable derivative is in the range of about 10 mg / mL to about 60 mg / mL. 4. The room-temperature stable, dilution-free injectable formulation according to claim 1 or 2, further comprising a plurality of pharmaceutically acceptable excipients, said pharmaceutically acceptable excipients being selected from antioxidants, buffers, preservatives, and surfactants. 5. The room-temperature stable, dilution-free injectable formulation according to claim 1 or 2, wherein the suitable ratio (w / w) of the solvent to carfilzomib or a pharmaceutically acceptable derivative thereof is about 100:1 to 8:1. 6. The room-temperature stable, dilution-free injectable formulation according to claim 4, wherein the antioxidant is selected from hydroxytoluene, butylated hydroxyanisole, propyl gallate, and C-tocopherol, DL-tocopherol, C-tocopherol acetate, C-tocopherol-tocopherol polyethylene glycol succinate (vitamin E). 7. The room-temperature stable, dilution-free injectable formulation according to claim 6, wherein the antioxidant is present at a concentration of about 0.005% to about 5% by weight of the total composition. 8. The room-temperature stable, dilution-free injectable formulation according to claim 1 or 2, wherein the formulation is stored at 25°C and 60% relative humidity or at 40°C and 75% relative humidity. 9. The room-temperature stable, dilution-free injectable formulation according to claim 1 or 2, wherein the formulation contains no more than 5%, no more than 4%, no more than 3%, no more than 2%, no more than 1.5%, no more than 1%, or no more than 0.5% total impurities after the expiration of the storage period. 10. A method for treating a patient with relapsed or refractory multiple myeloma, the method comprising administering a room-temperature stable, dilutable, injectable formulation of one or more solvents, carfilzomib preparations, or pharmaceutically acceptable derivatives thereof; wherein the formulation contains no more than 6% total impurities after storage for at least six months. 11. The method of claim 10 for treating a patient with relapsed or refractory multiple myeloma, wherein the dilutable, injectable formulation is stable after storage for at least six months. 12. A method of administering a reconstituted, dilutable formulation, the method comprising mixing component 1 and component 2 to form the reconstituted, diluting the reconstituted, diluting the reconstituted, dilutable formulation with an infusion medium; wherein component 1 comprises a room-temperature stable, dilutable formulation of carfilzomib or a pharmaceutically acceptable derivative thereof, and is stable after storage for at least six months.The total impurities do not exceed 6% after three months; and component 2 is an acidifier. 13. The method of administering a reconstituted, i.e., diluted formulation according to claim 12, wherein components 1 and 2 are in the range of about 10 mg / mL to about 60 mg / mL. 14. The method of administering a reconstituted, i.e., diluted formulation according to claim 12 or 13, wherein a suitable ratio (w / w) of the acidifier mixed with carfilzomib or a pharmaceutically acceptable derivative thereof is selected from about 1:50 to about 1:1. 15. The method of administering a reconstituted, i.e., diluted formulation according to claim 12 or 13, wherein component 1 is stored at 25°C and 60% relative humidity or at 40°C and 75% relative humidity for at least three months. 2 CN 121465991 A Claim 2 / 2 16. The method of administering a reconstituted, dilute formulation according to claim 12 or 13, wherein component 1 comprises a room-temperature stable, dilute formulation of carfilzomib or a pharmaceutically acceptable derivative thereof, and contains no more than 6% total impurities after storage for at least six months. 17. The method of administering a reconstituted, dilute formulation according to claim 12 or 13, wherein component 1 contains no more than 5%, no more than 4%, no more than 3%, no more than 2%, no more than 1.5%, no more than 1%, or no more than 0.5% total impurities after the storage period. 18. The method of giving a reconstituted diluent preparation according to claim 12 or 13, wherein the acidifying agent is selected from citric acid, acetic acid, maleic acid, phosphoric acid, succinic acid, succinic acid, ascorbic acid, misulfonic acid, Al2ic acid, succinic acid, succinic acid, succinic acid, gluconic acid, misulfonic acid, succinic acid, p-toluenesulfonic acid, succinic acid, lactose butyric acid, lactic acid, lactose butyric acid, edetate, succinic acid, metaphosphate, nitric acid, pentilic acid, glycolic acid, or wet media thereof. 19. A method for treating patients with relapsed or refractory multiple myeloma, the method comprising administering: a method of administering an instantaneous dilution preparation, comprising mixing component 1 and component 2 to form an instantaneous dilution preparation, and then diluting the instantaneous dilution preparation with an infusion medium; wherein component 1 is a room-temperature stable instantaneous parenteral preparation of a pharmaceutically acceptable derivative, component 2 is an acidifier, and wherein, when the mixture is stored at room temperature, the reconstituted instantaneous composition contains no more than 2% total impurities for up to 6 hours after mixing. 20. The method of claim 19 for treating patients with relapsed or refractory multiple myeloma, wherein, when the mixture is stored at room temperature, the reconstituted instantaneous composition contains no more than 2% total impurities for up to 6 hours after mixing.Containing no more than 1% total impurities, containing no more than 2% total impurities within 5 hours after mixing, containing no more than 1% total impurities within 5 hours after mixing, containing no more than 2% total impurities within 4 hours after mixing, or containing no more than 1% total impurities within 4 hours after mixing. 3 CN 121465991 A Specification 1 / 30 Page Stable, ready-to-dilute formulation of carfilzomib

[0001] This application is a divisional application of Chinese patent application No. 202180039555.5, filed on April 15, 2021, entitled "Stable, ready-to-dilute formulation of carfilzomib". Technical Field

[0002] The present invention relates to room temperature stable injectable formulations of carfilzomib or pharmaceutically acceptable derivatives thereof, which are in the form of ready-to-dilute solutions and concentrates. Furthermore, this invention relates to a method for treating patients with relapsed or refractory multiple myeloma, the method comprising administering a dilution of a fraction, comprising mixing component 1 and component 2 to form a dilution of a fraction, wherein component 1 is stored at room temperature for at least one time. Background Art

[0003] Carfilzomib is a selective protease inhibitor suitable for the treatment of multiple myeloma. Carfilzomib is a tetrapeptide epoxyketone protease inhibitor, M: irreversibly binding to the active site of the N-terminal threonine of the 20S protease, i.e., the proteolytic core particle of the 26S protease.

[0004] Carfilzomib is commercially marketed under the name Kyprolis®, and is available in vials containing 10 mg, 30 mg and 60 mg of the active ingredient. In addition to lyophilized carfilzomib, each vial also contains sodium bismuth subhydrate, citric acid, and sulfobutyl ether P-cyclodextrin for β-regulation.

[0005] A problem associated with commercially available formulations is that the reconstitution of lyophilized products is complex and cumbersome. Because the reconstitution process is complex, it involves aseptically reconstitution of each vial by slowly injecting sterile injectable water through the stopper, directing the water to the inner wall of the vial to ensure minimal foam formation. If foam appears, one must wait for the foam to settle and subside until the solution becomes clear. Furthermore, in reconstituted products, it is crucial to visually inspect the solution before administration; if the reconstituted solution appears to have any discoloration or particulate matter, it must be discarded. Additionally, it is known that excessive foam can lead to loss of efficacy.

[0006] Efforts have been made to obtain improved carfilzomib compositions. For example, substituted cyclodextrin binders have been explored to enhance the solubility of carfilzomib.

[0007] Because carfilzomib is sensitive to degradation, the development of a cost-effective, room-temperature stable carfilzomib injection is very important.The challenge remains. Improved carfilzomib formulations with improved ease of manufacture, administration route, and stability over time, particularly when stored at room temperature, are still needed. Summary of the Invention

[0008] One object of the present invention is to provide a room-temperature stable, dilution-type injectable formulation comprising carfilzomib or a pharmaceutically acceptable derivative thereof.

[0009] Another object of the present invention is to provide a method for treating patients with multiple myeloma by administering a room-temperature stable, dilution-type injectable formulation comprising carfilzomib or a pharmaceutically acceptable derivative thereof.

[0010] Furthermore, an object of the present invention is to provide a method for treating patients with relapsed or refractory multiple myeloma, the method comprising administering a reconstituted, dilute solution, comprising mixing component 1 and component 2 to form a reconstituted, dilute solution, and then diluting the reconstituted, dilute solution with an infusion medium; wherein component 1 is a room-temperature stable, dilute, parenteral preparation of carfilzomib or a pharmaceutically acceptable salt thereof; and component 2 is an acidifier.

[0011] In one aspect, the present invention provides a room-temperature stable carfilzomib preparation that is stable for at least one hour when stored at 25°C.

[0012] A carfilzomib formulation is provided in a formulation that is stable at room temperature and generally stable when stored at 5°C for at least one hour, wherein the total impurities of the formulation do not exceed 6%, preferably not more than 5%, preferably not more than 4%, preferably not more than 3%, preferably not more than 2%, preferably not more than 1.5%, preferably not more than 1%, preferably not more than 0.5%. Detailed Description

[0013] Unless the context clearly specifies otherwise, the numerical forms “a,” “an,” and “the” used in the specification and appended claims refer to all pronouns.

[0014] As used herein, the term “about” means within ±5% of the contents of the formulation.

[0015] As used herein, the terms “optional” or “optionally” mean that the minor events or conditions described below may or may not occur.

[0016] The formulations of the present invention comprise “carfilzomib” or a pharmaceutically acceptable derivative thereof. The pharmaceutically acceptable derivatives include pharmaceutically acceptable salts, solvates, hydrates, anhydrous forms, enantiomers, isomers, polyforms, tautomers, or mixtures thereof.

[0017] A pharmaceutically acceptable salt is one that retains the desired biological activity of the parent compound without conferring undesirable phytochemical effects. Examples of such salts are acid addition salts formed with inorganic acids, such as hydrochloric acid, chlorobromic acid, sulfuric acid, phosphoric acid, and nitric acid.Acids, etc.; salts formed with organic acids, such as acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, and polygalacturonic acid, etc.; salts formed by elemental anions, such as fluorides, bromides, and iodides; salts formed by metal hydroxides, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, and magnesium hydroxide; salts formed by metal carbonates, such as sodium carbonate, potassium carbonate, calcium carbonate, and magnesium carbonate; salts formed by metal nitrogen carbonates, such as sodium bicarbonate and potassium carbonate; salts formed by metal sulfates, such as sodium sulfate and potassium sulfate; and salts formed by metal nitrates, such as sodium nitrate and potassium nitrate. [8] The term "stable formulation" or "stabilized formulation" refers to any formulation of carfilzomib that has sufficient physical and chemical stability to allow storage at a convenient temperature for a reasonable period of time.

[0029] As used herein, the term “room temperature” means a temperature of about 15°C to about 40°C.

[0020] As used herein, the term “carfilzomib impurity” means any compound resulting from the chemical degradation of carfilzomib. Exemplary degradation pathways include, but are not limited to, hydrolysis, oxidation, epimerization of amides and / or epoxides, and products resulting from ethylene oxide ring-opening with various nucleophiles.

[0021] As used herein, the term “ready-to-dilute” means a formulation of carfilzomib or a pharmaceutically acceptable derivative thereof that can be directly combined with an infusion medium (e.g., dextran solution, water for injection, Ringer's solution, isotonic sodium chloride solution, suitable non-aqueous solvent, or any other infusion medium) and then administered to a patient. In some embodiments, the ready-to-dilute formulation may be provided in a single vial containing an injectable formulation comprising carfilzomib or a pharmaceutically acceptable derivative thereof. Optionally, the ready-to-dilute formulation may be further diluted with other suitable excipients prior to combination with an infusion medium.

[0022] As used herein, the term "component 1" refers to a carfilzomib or a pharmaceutically acceptable derivative thereof in an immediately dilute formulation.

[0023] As used herein, the term "component 2" refers to an acidifier that, together with component 1, forms an immediately dilute formulation, which may optionally be further added to or mixed into an infusion medium. Component 2 is used in the form of a clarified solution or powder.

[0024] As used herein, the term "reconstituted ready to dilute" means a formulation of carfilzomib or a pharmaceutically acceptable derivative thereof obtained by mixing component 1 and component 2 before adding to an infusion medium.

[0025] The term "ready to use" refers to..."Carfilzomib is a pharmaceutically acceptable derivative of the present invention that can be administered directly to the patient without any further dilution or treatment.

[0026] The formulations of the present invention are injectable formulations. Injectable formulations of carfilzomib or its pharmaceutically acceptable derivatives according to the present invention can be administered via any route including intramuscular, intravenous, or subcutaneous administration. Preferably, the injectable formulations of the present invention are administered intravenously. Carfilzomib or its pharmaceutically acceptable derivatives are in the form of a liquid concentrate, i.e., a diluted or ready-to-use solution. The injectable formulation can be packaged in a conventional sterile vial or other suitable sterile container.

[0027] In one embodiment, a room-temperature stable, diluted injectable formulation containing carfilzomib or its pharmaceutically acceptable derivatives contains carfilzomib at a concentration of about 5 mg / mL to about 350 mg / mL." In one embodiment, the concentration of carfilzomib is in the range of about 10 mg / mL to about 100 mg / mL, or about 15 mg / mL to about 60 mg / mL, or about 10 mg / mL to about 60 mg / mL. In a preferred embodiment, the injectable formulation is a formulation of carfilzomib at a concentration of about 10 mg / mL or about 60 mg / mL.

[0028] In one embodiment, the present invention provides a room temperature stable injectable diluent formulation comprising carfilzomib or a pharmaceutically acceptable derivative thereof and one or more solvents. In one embodiment, the diluent composition may comprise one or more solvents selected from ethanol, isopropanol, benzyl alcohol, propylene glycol, polyethylene glycol, acetamide (10A), N-methylpyrrolidone, dimethyl sulfoxide (10SO), diethylene glycol monoethyl ether, capryloyl hexanoyl polyoxyl-8 glycerides, tetrafluorofuran polyethylene glycol ether, or mixtures thereof. In a preferred embodiment, the formulation may comprise ethanol, dimethylacetamide, propylene glycol, polyethylene glycol, or mixtures thereof. In one embodiment, the ratio of one or more solvents used to carfilzomib or a pharmaceutically acceptable derivative thereof may vary from about 100:1 to 8:1.

[0029] In one embodiment, the room-temperature stable injectable formulation of the present invention may optionally comprise one or more pharmaceutically acceptable excipients, such as buffers, surfactants, antioxidants, and preservatives.

[0030] The formulation may comprise one or more pharmaceutically acceptable surfactants. Suitable surfactants include anionic surfactants, cationic surfactants, amphoteric surfactants, and nonionic surfactants; exemplary nonionic surfactants include polyethylene oxide, such as PEG 300 or PEG 400. Pharmaceutically acceptable for use in this applicationThe surfactants include, but are not limited to, polysorbate or polyethoxylated castor oil, polyoxyethylene 20 stearate, polyoxyethylene 35 castor oil, poloxamer, polyoxyethylene sorbitan monoisostearate, polyethylene glycol 40 sorbitan diisostearate, polyoxyethylene 40 hydrogenated castor oil, polysorbate, polysorbate ester 20, polysorbate 40, polyoxyethylene 60 stearate, polysorbate 80, polysorbate 60, poloxamer 331, polyoxyethylene fatty acid ester, polyoxyethylene 40 castor oil, poloxamer 188, polyoxyethylene polyoxypropylene 1800, oleic acid, sodium deoxycholate, sodium lauryl sulfate, sorbitan monolaurate, sorbitan monooleate, and sorbitan mono6. CN 121465991 A Instruction Manual, Page 4 / 30: Palmitate, Sorbitol Trioleate, N-Carbamoyl Methoxy polyethylene glycol 2000-1,2-distearol, Myristic Acid, Stearyl Ether, Stearic Acid, Polyethylene 40 Stearate, Sucrose Stearate, Phenolic Acid, Triglyceride Synthesis, Trimyristic Glyceryl Tristearate, Magnesium Stearate, Lecithin, Lauryl Sulfate, Vitamin E, Vitamin E-TPGS, Egg Yolk Lecithin, Sodium Docusate, Dimyristicophosphatidylglycerol, Dimyristicolecithin, Capryol 90 (Propylene Glycol Monocaprylate), Capryol PGMC Dimethyl Glycol Caprylate, Desmoyl Creatine Acetate, Inositol, Polyethylene Castor Oil (Cremophor EL), Alginate, Croval A-10 (PEG 60^( 11'Shanku), Labrafil 1944 (oleoyl macrogol-6 glyceride), Labrafil J 2125 (inoleoyl macrogol-6 glyceride), Labrasol (caprylocaproyl macrogol-8 glyceride), Lauroglycol 90 (Lauroglycol monolaurate), Calcium stearate, Lecithin Centromix E, Lecithin Centrophase 152, Lecithin Centrol 3F21B, POE 26, 01epal isosteariques(PEG-6 isostearate), Plurol diisostearique (poly(diisostearate)), Plurol Oleique CC, POE 20 sorbitan trioleate, Tagat TO (polyoxyethylene glycosyl trioleate), or Solutol (poly(ethylene glycol-15) hydroxy stearate). In some embodiments, optionally, the surfactant may comprise about 10% to about 90% of the total weight of the diluent formulation, preferably about 20% to about 80% of the total weight of the diluent formulation, and preferably about 30% to about 60% of the total weight of the diluent formulation.

[0031] The formulation may contain a buffer selected from a mixture of a weak acid and an alkali metal salt (e.g., sodium, potassium) and the conjugate base of the weak acid. Suitable buffers include, for example, buffers selected from the group consisting of citric acid, acetic acid, etc. Maleic acid, phosphoric acid, succinic acid, tartaric acid, ascorbic acid, benzoic acid, oxalic acid, fumaric acid, gluconic acid, malic acid, mesylic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, galacturonic acid, lactic acid, lactobionic acid, edetic acid, gentian acid, metaphosphoric acid, nitric acid, pentimic acid, glycolic acid, and their counterion salts.

[0032] The formulation may contain one or more anti-bismuth agents, wherein the anti-bismuth agents are selected from butylated hydroxytoluene, butylated hydroxyanisole, propyl gallate, and C-tocopherol, DL-tocopherol, C-tocopherol acetate, C-tocopherol tocopherol polyethylene glycol succinate (vitamin E). The formulation may contain TPGS, L-cysteine ​​ascorbate palmitate thioglycolic acid, sodium metabisulfite (SMBS), ascorbic acid, sodium formaldehyde sulfoxylate, or hydrophilic antioxidants, including sodium EDTA and thioglycerol. Most typically, the concentration of the antioxidant is from 0.005% (wt / wt) to 5% (wt / wt) of the total composition.

[0033] The formulation may contain a preservative selected from phenol, thimerosal, chlorobutanol, benzyl alcohol, m-cresol, phenoxyethanol, methylparaben, and propylparaben, typically from 0.01% (wt / wt) to about 5% (wt / wt) of the total composition, and most typically from about 0.003% (wt / wt) to about 2.0% (wt / wt) of the total composition.

[0034] The formulation may contain an acidifying agent selected from citric acid, acetic acid, maleic acid, phosphoric acid, succinic acid, tartaric acid, ascorbic acid, benzenesulfonic acid, oxalic acid, fumaric acid, gluconic acid, malic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, galacturonic acid, lactic acid, lactobionic acid, edemaic acid, gentianic acid, and metabenzeneic acid.Phosphoric acid, nitric acid, pentiacic acid, glycolic acid. The purpose of using acidifying agents in this invention is to maintain an acidic pH, thereby allowing carfilzomib or its pharmaceutically acceptable salts to dissolve in the infusion medium. Additionally, the purpose of using acidifying agents in this invention is to prevent drug precipitation in the infusion medium.

[0035] Certain compounds have been identified as impurities obtained from the degradation of carfilzomib and stability samples have been analyzed, such as [acid impurities] (S)-2-((S)-4-methyl-2-((S)-2-(2-morpholinoacetamyl)-4-phenylbutamido)pentamido)-3-phenylpropionic acid; [diasteremeric impurities] (5)-4-methyl-N-((R)-1-((5)-4-methyl((8-2-7 CN 121465991 A Specification 5 / 30 methylepoxyethylene-2-yl)-1-oxopentane-2-yl)amino)-1-bismuth-3-phenylpropane-2-yl)-2-((S)-2-(2- Morpholinoacetamyl)-4-phenylbutamido)pentanamide; [Phenolic impurity] 2,3,4,5,6-pentabiphenylphenol; [Diol impurity] (S)-N-((S)-1-(((2R,4S)-1,2-dihydroxy-2,6-dimethyl-3-chloroheptane-4-yl)nuyl)-1-M-3-phenylpropane-2-yl)-4-methyl-2-((S)-2-(2-morpholinoacetamyl)-4-phenylbutamido)pentanamide; [Chlorine impurity] (S)-N-((S)-1-(((2S,4S)-1-chloro-2-yl-2,6-dimethyl-3-M-methylpropane-4-yl)nuyl)-1-M-3-phenylpropane-2-yl)-4-lfl-2-((S)-2- (2-morpholinoacetamide)-4-benzylaminoacetamide)pentanamide; [N-oxide impurities] 4-((4S,7S,10S,13S)-10-benzyl-7-butyl-15-111-13-((R)-ethylene oxide-2-carbonyl)-2,5,8,11-tetraoxo-4-phenylethyl-3,6,9,12-tetraaza-hexadecyl)morpholino-4-methyl compound.

[0036] In one embodiment, the total impurities formed during storage in the temperature-stable formulation do not exceed 6%. In another embodiment, the total impurities formed during storage in the room-temperature-stable formulation do not exceed 5%. In another embodiment, the total impurities formed during storage in the room-temperature-stable formulation do not exceed 4%. In one embodiment, the total impurities of the room-temperature stable formulation that form during storage do not exceed 3%. In another embodiment, the total impurities of the room-temperature stable formulation that form during storage do not exceed 2%.In this embodiment, the total amount of impurities formed during the storage period in the room-temperature stable formulation does not exceed 1%. In one embodiment, the total amount of impurities formed during the storage period in the room-temperature stable formulation does not exceed 0.5%. In one embodiment, the storage period of the formulation of the present invention can be a reasonable period during which the formulation has sufficient chemical and physical stability. The storage period can be selected, for example, at least about one hour, at least about three months, at least about six months, at least about one year, or at least about two years.

[0037] In one embodiment, the room-temperature stable formulation refers to any formulation of carfilzomib that has sufficient stability to allow storage at room temperature, such as about 15 °C to about 40 °C; preferably about 20 °C to about 40 °C; more preferably about 25 °C to about 40 °C; and most preferably about 20 °C to about 25 °C. It should be understood that the stability of the carfilzomib formulation within the temperature range of the embodiments always comes with the additional parameter of 60% humidity. In a preferred embodiment of the invention, the stability of the room-temperature stable formulation can be evaluated after storing the formulation of the invention in a sealed, sterile container at 25°C and 60% relative humidity.

[0038] In one embodiment, the invention provides a room-temperature stable carfilzomib formulation that is stable for at least one month when stored at 40°C and 75% relative humidity. In one embodiment, the invention provides a room-temperature stable carfilzomib formulation that is stable for at least three months when stored at 40°C and 75% relative humidity. In one embodiment, the invention provides a room-temperature stable carfilzomib formulation that is stable for at least six months when stored at 40°C and 75% relative humidity. In one embodiment, the invention provides a room-temperature stable carfilzomib formulation that is stable for at least one year when stored at 40°C and 75% relative humidity.

[0039] In one embodiment, the invention provides a room-temperature stable carfilzomib formulation that is stable for at least two years when stored at 40°C and 75% relative humidity. The stability of the formulation of the present invention is measured by fi, the total impurities formed at the end of the stability period. In one embodiment, stability is achieved when the impurities formed during the specified stability period do not exceed 6%, preferably not more than 5%, preferably not more than 4%, preferably not more than 3%, preferably not more than 2%, preferably not more than 1.5%, preferably not more than 1%, preferably not more than 0.5%. [0(M0)] In one embodiment, after storage at 75% RH and 40°C for one month, the carfilzomib composition is able to have a total impurity of not more than 6% as determined by HPLC. In one embodiment, at 75% RH and 40°C...After one month of storage, the carfilzomib composition exhibits a total impurity content of no more than 5% as determined by HPLC. In one embodiment (see page 6 / 30 of specification 8 CN 121465991 A), after storage at 75% RH and 40°C for one month, the carfilzomib composition exhibits a total impurity content of no more than 4% as determined by HPLC. In another embodiment, after storage at 75% RH and 40°C for one month, the carfilzomib composition exhibits a total impurity content of no more than 3% as determined by HPLC. In one embodiment, after storage at 75% RH and 40°C for one month, the carfilzomib composition exhibits no more than 2% total impurities as determined by HPLC. In another embodiment, after storage at 75% RH and 40°C for one month, the carfilzomib composition exhibits no more than 1.5% total impurities as determined by HPLC. In another embodiment, after storage at 75% RH and 40°C for one month, the carfilzomib composition exhibits no more than 1% total impurities as determined by HPLC. In yet another embodiment, after storage at 75% RH and 40°C for one month, the carfilzomib composition exhibits no more than 0.5% total impurities as determined by HPLC.

[0041] In one embodiment, after three months of storage at 75% RH and 40°C, the carfilzomib composition can have a total impurity content of no more than 6% as determined by HPLC. In one embodiment, after three months of storage at 75% RH and 40°C, the carfilzomib composition can have a total impurity content of no more than 5% as determined by HPLC. In another embodiment, after three months of storage at 75% RH and 40°C, the carfilzomib composition can have a total impurity content of no more than 4% as determined by HPLC. In one embodiment, after three months of storage at 75% RH and 40°C, the carfilzomib composition can have a total impurity content of no more than 3% as determined by HPLC. In one embodiment, at 75% RH and 40°C... After storage at RH and 40°C for three months, the carfilzomib composition can contain no more than 2% total impurities as determined by HPLC. In one embodiment, after storage at 75% RH and 40°C for three months, the carfilzomib composition can contain no more than 1.5% total impurities as determined by HPLC. In one embodiment, after storage at 75% RH and 40°C for three months, the carfilzomib composition can contain no more than 1% total impurities as determined by HPLC. In one embodiment, after storage at 75% RH and 40°C for three months, the carfilzomib composition can contain no more than 0.5% total impurities as determined by HPLC.

[0042] In one embodiment, at 75% RH and 40°C for three months, the carfilzomib composition can contain no more than 0.5% total impurities as determined by HPLC.After six months of storage at RH and 40°C, the carfilzomib composition exhibits a total impurity content of no more than 6% as determined by HPLC. In one embodiment, after six months of storage at 75% RH and 40°C, the carfilzomib composition exhibits a total impurity content of no more than 5% as determined by HPLC. In another embodiment, after six months of storage at 75% RH and 40°C, the carfilzomib composition exhibits a total impurity content of no more than 4% as determined by HPLC. In another embodiment, after six months of storage at 75% RH and 40°C, the carfilzomib composition exhibits a total impurity content of no more than 3% as determined by HPLC. In another embodiment, after six months of storage at 75% RH and 40°C, the carfilzomib composition exhibits a total impurity content of no more than 2% as determined by HPLC. In yet another embodiment, after six months of storage at 75% RH and 40°C, the carfilzomib composition exhibits a total impurity content of no more than 1.5% as determined by HPLC. In one embodiment, after storage at 75% RH and 40°C for six months, the carfilzomib composition exhibits a total impurity content of no more than 1% as determined by HPLC. In another embodiment, after storage at 75% RH and 40°C for six months, the carfilzomib composition exhibits a total impurity content of no more than 0.5% as determined by 1IPLC. In one embodiment, the present invention provides a room-temperature stable carfilzomib formulation that is stable for at least one month when stored at 25°C and 60% relative humidity. In another embodiment, the present invention provides a room-temperature stable carfilzomib formulation that is stable for at least three months when stored at 25°C and 60% relative humidity. In yet another embodiment, the present invention provides a room-temperature stable carfilzomib formulation that is stable for at least six months when stored at 25°C and 60% relative humidity. In yet another embodiment, the present invention provides a room-temperature stable carfilzomib formulation that is stable for at least one year when stored at 25°C and 60% relative humidity. 9 CN 121465991 A Specification 7 / 30 pages

[0044] In one embodiment, the present invention provides a carfilzomib formulation that is stable at room temperature. It is stable for at least two years when stored at 25°C and 60% relative humidity. The stability of the formulation of the present invention is measured by the total impurities formed at the end of the stability period. In one embodiment, stability is achieved when the impurities formed during the specified stability period do not exceed 6%, preferably not more than 5%, preferably not more than 4%, preferably not more than 3%, preferably not more than 2%, preferably not more than 1.5%, preferably not more than 1%, preferably not more than 0.5%.

[0045] In one embodiment 11.1, 60%In one embodiment, after storage at 125°C for one month, the zomib composition can have no more than 6% total impurities as determined by HPLC. In another embodiment, after storage at 60% RH and 25°C for one month, the zomib composition can have no more than 5% total impurities as determined by HPLC. In one embodiment, after storage at 60% RH and 25°C for one month, the carfilzomib composition exhibits a total impurity content of no more than 2% as determined by HPLC. In another embodiment, after storage at 60% RH and 25°C for one month, the carfilzomib composition exhibits a total impurity content of no more than 1.5% as determined by HPLC. In one embodiment, after storage at 60% RH and 25°C for one month, the carfilzomib composition exhibits a total impurity content of no more than 1% as determined by HPLC. In another embodiment, after storage at 60% RH and 25°C for one month, the carfilzomib composition exhibits a total impurity content of no more than 0.5% as determined by HPLC.

[0046] In one embodiment, after storage at 60% RH and 25°C for three months, the carfilzomib composition is able to contain no more than 6% total impurities as determined by HPLC. In one embodiment, after storage at 60% RH and 25°C for three months, the carfilzomib composition is able to contain no more than 5% total impurities as determined by HPLC. In one embodiment, after storage at 60% RH and 25°C for three months, the carfilzomib composition is able to contain no more than 4% total impurities as determined by HPLC. In one embodiment, after storage at 60% RH and 25°C for three months, the carfilzomib composition is able to contain no more than 3% total impurities as determined by HPLC. In one embodiment, after storage at 60% RH and 25°C for three months, the carfilzomib composition is able to contain no more than 2% total impurities as determined by HPLC. In one embodiment, after storage at 60% RH and 25°C for three months, the carfilzomib composition is able to contain no more than 1.5% total impurities as determined by HPLC. In one embodiment, after storage for three months at 60% RH and 25°C, the carfilzomib composition exhibits a total impurity content of no more than 1% as determined by HPLC. In another embodiment, at 60% RH...After being stored at 25°C for three months, the carfilzomib composition can have a total impurity content of no more than 0.5% as determined by HPLC.

[0047] In one embodiment, after being stored at 60% RH and 25°C for six months, the carfilzomib composition can have a total impurity content of no more than 6% as determined by HPLC. In one embodiment, after being stored at 60% RH and 25°C for six months, the carfilzomib composition can have a total impurity content of no more than 5% as determined by HPLC. In one embodiment, after being stored at 60% RH and 25°C for six months, the carfilzomib composition can have a total impurity content of no more than 4% as determined by HPLC. In one embodiment, after being stored at 60% RH and 25°C for six months, the carfilzomib composition can have a total impurity content of no more than 3% as determined by HPLC. In one embodiment, after being stored at 60% RH and 25°C for six months, the carfilzomib composition can have a total impurity content of no more than 2% as determined by HPLC. In one embodiment, after storage for six months at 60% RH and 25°C, the carfilzomib composition exhibits a total impurity content of no more than 1.5% as determined by HPLC. In one embodiment, after storage for six months at 60% RH and 25°C, the carfilzomib composition exhibits a total impurity content of no more than 1% as determined by HPLC. In one embodiment, after storage for six months at 60% RH and 25°C, the carfilzomib composition exhibits a total impurity content of no more than 0.5% as determined by HPLC.

[0048] In one embodiment, the present invention provides a room-temperature stable injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents.

[0049] In one embodiment, the present invention provides a room temperature stable injectable formulation comprising: ozonil, a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients, said excipients being selected as antioxidants, buffers, preservatives, and surfactants.

[0050] In another embodiment, the present invention provides a room temperature stable injectable formulation comprising: ozonil, a pharmaceutically acceptable salt thereof, and a variety of solvents; wherein said injectable formulation comprises an isocyanate, a concentrated extract. In a preferred embodiment, the injectable formulation of the present invention comprises a room temperature stable isocyanate solution.

[0051] In one embodiment, the present invention provides a room temperature stable isocyanate injectable formulation comprising: ozonil or a pharmaceutically acceptable salt thereof and one or more solvents.

[0052] In one embodiment, the present invention provides a room temperature stable, immediately diluted injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients, said excipients being selected from antioxidants, buffers, preservatives, and surfactants.

[0053] In one embodiment, the present invention provides a room temperature stable, immediately diluted injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein said formulation contains no more than 6% total impurities after one month of storage.

[0054] In one embodiment, the present invention provides a room temperature stable, immediately diluted injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein said formulation contains no more than 5% total impurities after one month of storage.

[0055] In one embodiment, the present invention provides a room temperature stable, immediately diluted injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein said formulation contains no more than 4% total impurities after one month of storage.

[0056] In one embodiment, the present invention provides a room-temperature stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein, the formulation contains no more than 3% total impurities after one month of storage.

[0057] In one embodiment, the present invention provides a room-temperature stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein, the formulation contains no more than 2% total impurities after one month of storage.

[0058] In one embodiment, the present invention provides a room-temperature stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein, the formulation contains no more than 1.5% total impurities after one month of storage.

[0059] In one embodiment, the present invention provides a room-temperature stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein, the formulation contains no more than 1.0% total impurities after one month of storage.

[0060] In one embodiment, the present invention provides a room-temperature stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein, the formulation contains no more than 0.5% total impurities after one month of storage. 11 CN 121465991 A Specification 9 / 30 pages

[0061] In one embodiment, the present invention provides a stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable derivative thereof and one or more solvents; wherein, when stored at 25°C and 60% relative humidity, the formulation contains no more than 6% total impurities after one month of storage.

[0062] In one embodiment, the present invention provides a stable, immediately dilution injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof; a solvent or a combination of solvents; and optionally one or more pharmaceutically acceptable excipients, said excipients being selected as antioxidants, buffers, preservatives, and surfactants. When stored at 25°C and 60% relative humidity, the formulation contains no more than 6% total impurities after one month of storage.

[0063] In one embodiment, the present invention provides a stable, immediately dilution injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; a solvent or a combination of solvents; and optionally one or more pharmaceutically acceptable excipients, said excipients being selected as antioxidants, buffers, preservatives, and surfactants. When stored at 25°C and 60% relative humidity, the formulation contains no more than 5% total impurities after one month of storage.

[0064] In one embodiment, the present invention provides a stable, immediately dilution, injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25 °C and 60% relative humidity, the formulation contains no more than 4% total impurities after one hour of storage.

[0065] In one embodiment, the present invention provides a stable, immediately dilution, injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25 °C and 60% relative humidity, the formulation contains no more than 3% total impurities after one hour of storage.

[0066] In one embodiment, the present invention provides a stable, immediately dilution injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25 °C and 60% relative humidity, the formulation contains no more than 2% total impurities after one month of storage.

[0067] In one embodiment, the present invention provides a stable, immediately dilution injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25 °C and 60% relative humidity, the formulation contains no more than 1.5% total impurities after one month of storage.

[0068] In one embodiment, the present invention provides a stable, immediately dilution injectable formulation comprising carfilzomib.Or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25 °C and 60% relative humidity, the formulation contains no more than 1.0% total impurities after one month of storage.

[0069] In one embodiment, the present invention provides a stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25 °C and 60% relative humidity, the formulation contains no more than 0.5% total impurities after one month of storage.

[0070] In one embodiment, the present invention provides a room temperature stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein, the formulation contains no more than 6% total impurities after three months of storage.

[0071] In one embodiment, the present invention provides a room-temperature stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein the formulation contains no more than 5% total impurities after three months of storage.

[0072] In one embodiment, the present invention provides a room-temperature stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein the formulation contains no more than 4% total impurities after three months of storage.

[0073] In one embodiment, the present invention provides a room-temperature stable diluted injectable formulation comprising zomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein, the formulation has a total impurity content of more than 3% after storage for three months.

[0074] In one embodiment, the present invention provides a room-temperature stable diluted injectable formulation comprising zomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein, the formulation has a total impurity content of no more than 1.5% after storage for three months.

[0075] In one embodiment, the present invention provides a room-temperature stable diluted injectable formulation comprising zomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein, the formulation has a total impurity content of no more than 1.5% after storage for three months.

[0076] In one embodiment, the present invention provides a room-temperature stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein the formulation contains no more than 1.0% total impurities after storage for three months.

[0077] In one embodiment, the present invention provides a room-temperature stable, dilution-free injectable formulation comprising carfilzomib.Carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein, the formulation contains no more than 0.5% total impurities after three months of storage. [E0078] In one embodiment, the present invention provides a stable, dilutionable injectable formulation comprising carfilzomib or a pharmaceutically acceptable derivative thereof and one or more solvents; wherein, when stored at 25 °C and 60% relative humidity, the formulation contains no more than 6% total impurities after three months of storage. [T0079] In one embodiment, the present invention provides a stable, dilutionable injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25 °C and 60% relative humidity, the formulation contains no more than 6% total impurities after three months of storage.

[0080] In one embodiment, the present invention provides a stable, dilutionable injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25 °C and 60% relative humidity, the formulation contains no more than 5% total impurities after three months of storage.

[0081] In one embodiment, the present invention provides a stable, dilutionable injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25 °C and 60% relative humidity, the formulation contains no more than 4% total impurities after three months of storage.

[0082] In one embodiment, the present invention provides a stable, dilutionable injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25°C and 60% relative humidity, the formulation contains no more than 3% total impurities after three months of storage. 13 CN 121465991 A Specification 11 / 3()

[0083] In one embodiment, the present invention provides a stable, dilutionable injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25°C and 60% relative humidity, the formulation contains no more than 2% total impurities after three months of storage.[00841 In one embodiment, the present invention provides / represents a dilutionable injectable formulation, comprising: a bismuth subsalicylate or cyclophosphamide, a salt thereof; a bismuth subsalicylate or cyclophosphamide; and optionally a bismuth subsalicylate or cyclophosphamide, wherein the excipient is selected as an anti-bismuth agent, a buffer, a preservative, and a activator; wherein, when stored at 25°C and 60% relative humidity, the formulation contains no more than 1.5% total impurities after three months of storage.]

[0085] In one embodiment, the present invention provides a stable, immediately dilution injectable formulation comprising: carfilzomib or a pharmaceutically acceptable salt thereof; a solvent of methylphenidate or methylphenidate; and optionally one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25°C and 60% relative humidity, the formulation contains no more than 1.0% total impurities after three months of storage.

[0086] In one embodiment, the present invention provides a stable, immediately dilution injectable formulation comprising: carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25°C and 60% relative humidity, the formulation contains no more than 0.5% total impurities after three months of storage.

[0087] In one embodiment, the present invention provides a room-temperature stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein the formulation contains no more than 6% total impurities after six months of storage.

[0088] In one embodiment, the present invention provides a room-temperature stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein the formulation contains no more than 5% total impurities after six months of storage.

[0089] In one embodiment, the present invention provides a room-temperature stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein the formulation contains no more than 4% total impurities after six months of storage.

[0090] In one embodiment, the present invention provides a room-temperature stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein the formulation contains no more than 3% total impurities after six months of storage. [f0091] In one embodiment, the present invention provides a room-temperature stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein the formulation contains no more than 2% total impurities after six months of storage. [w092] In one embodiment, the present invention provides a room-temperature stable, dilution-free injectable formulation comprising carfilzomib.Carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein, the formulation contains no more than 1.5% total impurities after six months of storage.

[0093] In one embodiment, the present invention provides a room temperature stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein, the formulation contains no more than 1.0% total impurities after six months of storage.

[0094] In one embodiment, the present invention provides a room temperature stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein, the formulation contains no more than 0.5% total impurities after six months of storage.

[0095] In one embodiment, the present invention provides a stable, dilution-free injectable formulation comprising carfilzomib or a pharmaceutically acceptable derivative thereof and one or more solvents; wherein, when stored at 25°C and 60% relative humidity, the formulation contains no more than 6% total impurities after six months of storage.

[0096] In one embodiment, the present invention provides a stable, immediately diluted injectable formulation containing zozamide or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients, said excipients being selected from antioxidants, buffers, preservatives, and activators; wherein, when stored at 25°C and 60% relative humidity, the formulation contains no more than 6% total impurities after six months of storage.

[0097] In one embodiment, the present invention provides a stable, immediately diluted injectable formulation containing zozamide or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients, said excipients being selected from antioxidants, buffers, preservatives, and activators; wherein, when stored at 25°C and 60% relative humidity, the formulation contains no more than 5% total impurities after six months of storage.

[0098] In one embodiment, the present invention provides a stable, immediately dilution injectable formulation comprising: carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients, said excipients being selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25 °C and 60% relative humidity, the formulation contains no more than 4% total impurities after six months of storage.

[0099] In one embodiment, the present invention provides a stable, immediately dilution injectable formulation comprising: carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients, said excipients being selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25 °C and 60% relative humidity, the formulation contains no more than 4% total impurities after six months of storage.During storage, the formulation contains no more than 3% total impurities after six months of storage. [00W0] In one embodiment, the present invention provides a stable, dilutionable injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25 °C and 60% relative humidity, the formulation contains no more than 2% total impurities after six months of storage.

[0101] In one embodiment, the present invention provides a stable, dilutionable injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25 °C and 60% relative humidity, the formulation contains no more than 1.5% total impurities after six months of storage. [0W2] In one embodiment, the present invention provides a stable, dilutionable injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25 °C and 60% relative humidity, the formulation contains no more than 1.0% total impurities after six months of storage. [0W3] In one embodiment, the present invention provides a stable, dilutionable injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants; wherein, when stored at 25 °C and 60% relative humidity, the formulation contains no more than 0.5% total impurities after six months of storage.

[0104] Having stable room-temperature injectable formulations is always desirable and beneficial, offering commercial and handling advantages compared to formulations stored under stringent conditions (e.g., 2-8 °C). However, obtaining injectable formulations that are stable at room temperature and have fewer impurities or impurity levels within limits acceptable to drug approval authorities is very challenging. 15 CN 121465991 A Specification 13 / 30 pages

[0105] During stability studies, it was surprisingly found that the immediate-dilute injectable solution without an acidifier had a significantly better impurity profile than the immediate-dilute injectable solution without an acidifier. Therefore, compared to the formulation without an acidifier, the acidifier negatively affects the stability of the formulation at room temperature and generates more impurities during the stable period. The better impurity profile described in this invention includes the difference in total impurities obtained during the stable period when the formulation sample is analyzed by HPLC.

[0106] In one embodiment, the present invention provides a temperature-stable injectable formulation comprising carfilzomib and pharmaceutically acceptable salts thereof, which is free from any acidifier.

[0107] In one embodiment, the present invention provides a temperature-stable injectable formulation comprising carfilzomib and pharmaceutically acceptable salts thereof, which is free from any acidifier during the stability period of the formulation.

[0108] In one embodiment, the present invention provides a temperature-stable injectable formulation comprising carfilzomib and pharmaceutically acceptable salts thereof; one or more excipients; and optionally one or more excipients selected from antioxidants, buffers, and surfactants; and which is free from any acidifier during the stability period of the formulation.

[0109] In one embodiment, the present invention provides a room-temperature stable, dilution-free injectable formulation comprising: 1h carfilzomib and a pharmaceutically acceptable salt thereof; one or more solvents; and optionally one or more excipients selected from antioxidants, buffers, and surfactants; and which is free of any acidifiers during the stability period of the formulation.

[0110] In one embodiment, the present invention relates to the delivery of a room-temperature stable, dilution-free injectable formulation of carfilzomib, which, once diluted to an appropriate injection (particularly infusion, most particularly intravenous infusion) concentration, can be administered at an appropriate dose for the treatment of carfilzomib-responsive conditions known in the art.

[0111] In one embodiment, the present invention provides a method for treating patients with relapsed or refractory multiple myeloma by administering, in combination with dexamethasone or lenalidomide plus dexamethasone, or by administering alone, a room-temperature stable, dilution-free or ready-to-use parenteral formulation of carfilzomib.

[0112] In one embodiment, the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, the method comprising administering a room-temperature stable, dilutionable injectable formulation of carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents; wherein the formulation contains no more than 6% total impurities after the expiration of its shelf life. In one embodiment, a method for treating a patient also with relapsed or refractory multiple myeloma comprises administering a formulation of carfilzomib or a pharmaceutically acceptable salt thereof, the formulation containing no more than 5% total impurities after the expiration of its shelf life. In one embodiment, a method for treating a patient with relapsed or refractory multiple myeloma comprises administering a formulation of carfilzomib or a pharmaceutically acceptable salt thereof, the formulation containing no more than 4% total impurities after the expiration of its shelf life. In one embodiment, a method for treating a patient with relapsed or refractory multiple myeloma comprises administering a formulation of carfilzomib or a pharmaceutically acceptable salt thereof, the formulation containing no more than 4% total impurities after the expiration of its shelf life.The formulation contains no more than 3% total impurities. In one embodiment, a method of treating a patient with relapsed or refractory multiple myeloma includes administering a formulation of carfilzomib or a pharmaceutically acceptable salt thereof, wherein the formulation contains no more than 2% total impurities after the expiration of its shelf life. In another embodiment, a method of treating a patient with relapsed or refractory multiple myeloma includes administering a formulation of carfilzomib or a pharmaceutically acceptable salt thereof, wherein the formulation contains no more than 1.5% total impurities after the expiration of its shelf life. In yet another embodiment, a method of treating a patient with relapsed or refractory multiple myeloma includes administering a formulation of carfilzomib or a pharmaceutically acceptable salt thereof, wherein the formulation contains no more than 1% total impurities after the expiration of its shelf life. In yet another embodiment, a method of treating a patient with relapsed or refractory multiple myeloma includes administering a formulation of carfilzomib or a pharmaceutically acceptable salt thereof, wherein the formulation contains no more than 0.5% total impurities after the expiration of its shelf life. 16 CN 121465991 A Specification 14 / 30 pages

[0113] In one embodiment, the present invention provides a method for treating patients with relapsed or refractory multiple myeloma, the method comprising administering a room-temperature stable, dilution-injectable formulation of carfilzomib or a pharmaceutically acceptable salt thereof, wherein the dilution-injectable formulation is stable when stored at 25°C and 60% relative humidity for one hour. Preferably, in one embodiment, the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, the method comprising administering a stable, indiluted injectable formulation of carfilzomib or a clinically accepted salt thereof, wherein the indiluted injectable formulation is stable for three months of storage at 25°C and 60% relative humidity. More preferably, in one embodiment, the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, the method comprising administering a stable, indiluted injectable formulation of carfilzomib or a clinically accepted salt thereof, wherein the indiluted injectable formulation is stable for six months of storage at 25°C and 60% relative humidity. [C0114] In one embodiment of the present invention, the present invention provides a method for treating relapsed or refractory multiple myeloma, the method comprising administering an i.e., diluted solution of the i.e., a combination of component 1 and component 2, followed by dilution with an infusion medium; wherein component 1 comprises a β-B-zome or a thermo-stable i.e., a dilute parenteral preparation, and component 2 is an acidifier.

[0115] In one embodiment of the present invention, component 2 comprises an acidifier, which may be selected from citric acid, malic acid, phosphoric acid, etc.Acids, orthophosphoric acid (OPA), fumaric acid, or mixtures thereof. In one embodiment, the ratio of the acidifier used to carfilzomib or a pharmaceutically acceptable salt thereof, based on w / w, is about 1:50 to about 1:1. In one embodiment, the ratio of the acidifier used to carfilzomib or a pharmaceutically acceptable salt thereof, based on w / w, is about 1:40 to about 1:1. In one embodiment, the ratio of the acidifier used to carfilzomib or a pharmaceutically acceptable salt thereof, based on w / w, is about 1:30 to about 1:1. In one embodiment, the ratio of the acidifier used to carfilzomib or a pharmaceutically acceptable salt thereof, based on w / w, is about 1:20 to about 1:1. In one embodiment, the ratio of the acidifier used to carfilzomib or a pharmaceutically acceptable salt thereof, based on w / w, is about 1:10 to about 1:1.

[0116] Component 2 is added to component 1 such that carfilzomib or a pharmaceutically acceptable salt thereof is readily degraded in a diluted parenteral solution at room temperature. In one embodiment, when the mixture of component 1 and component 2 is stored at room temperature, the mixture should not be used after 4 hours of mixing. In a preferred embodiment, when the mixture of component 1 and component 2 is stored at room temperature, the mixture should not be used after 5 hours of mixing. In a preferred embodiment, when the mixture of component 1 and component 2 is stored at room temperature, the mixture should not be used after 6 hours of mixing.

[01171] In a preferred embodiment, when the mixture of component 1 and component 2 is stored at 2-8°C, the mixture should not be applied to the infusion medium after 24 hours of mixing. In one embodiment, the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, the method comprising administering a reconstituted, dilute solution, comprising mixing component 1 and component 2 to form a reconstituted, dilute solution with an infusion medium; wherein component 1 is a room-temperature stable, dilute, parenteral preparation of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifier; and wherein, when the mixture of components 1 and component 2 is stored at room temperature, the mixture should not be used for administration after 4 hours of mixing.

[0119] In one embodiment, the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, the method comprising administering a reconstituted, dilute solution, comprising mixing component 1 and component 2 to form a reconstituted, dilute solution with an infusion medium; wherein component 1 is a room-temperature stable, dilute parenteral preparation of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifier (see page 15 / 30 of specification 17 CN 121465991 A); and wherein, when the mixture of components 1 and component 2 is stored at room temperature, the mixture does not deteriorate after 5 hours of mixing.It should be reused for administration.

[0120] In one embodiment, the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, the method comprising administering a reconstituted, dilute solution, comprising mixing component 1 and component 2 to form a reconstituted, dilute solution with an infusion medium; wherein, component 1 is a room-temperature stable, dilute parenteral preparation of fosfomycin or an acceptable salt thereof, and component 2 is an acidifier; wherein, when the mixture of component 1 and component 2 is stored at room temperature, the mixture is not administered for 6 hours.

[0121] In one embodiment, the present invention provides a method for treating patients with primary and refractory multiple myeloma, the method comprising administering a reconstituted diluent solution, comprising mixing component 1 and component 2 to form a reconstituted diluent solution, and then diluting the reconstituted diluent solution with an infusion medium; wherein component 1 is a room temperature stable reconstituted parenteral preparation of carfilzomib or a salt thereof, and component 2 is an acidifier; and wherein, when the mixture is stored at room temperature, the reconstituted diluent solution contains no more than 2% total impurities within a 4-hour period of time. [E0122] In one embodiment, the present invention provides a method for treating patients with relapsed or refractory multiple myeloma, the method comprising administering a reconstituted, dilute solution, comprising mixing component 1 and component 2 to form a reconstituted, dilute solution with an infusion medium; wherein component 1 is a room-temperature stable, dilute, parenteral preparation of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifier; and wherein, when the mixture is stored at room temperature, the reconstituted, dilute composition has no more than 1% total impurities for up to 4 hours after mixing.

[0123] In one embodiment, the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, the method comprising administering a reconstituted, dilute solution, comprising mixing component 1 and component 2 to form a reconstituted, dilute solution, and then diluting the reconstituted, dilute solution with an infusion medium; wherein component 1 is a room-temperature stable, dilute, parenteral preparation of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifier; and wherein, when the mixture is stored at room temperature, the reconstituted, dilute composition has no more than 2% total impurities for up to 5 hours after mixing.

[0124] In one embodiment, the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, the method comprising administering a reconstituted, dilute solution, comprising mixing component 1 and component 2...The components are mixed to form a reconstituted, dilute solution, which is then diluted with an infusion medium; wherein component 1 is a room-temperature stable, dilute parenteral preparation of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifier; and wherein, when the mixture is stored at room temperature, the reconstituted, dilute composition has no more than 1% total impurities for up to 5 hours after mixing.

[0125] In one embodiment, the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, the method comprising administering a reconstituted, dilute solution, comprising mixing component 1 and component 2 to form a reconstituted, dilute solution, which is then diluted with an infusion medium; wherein component 1 is a room-temperature stable, dilute parenteral preparation of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifier; and wherein, when the mixture is stored at room temperature, the reconstituted, dilute composition has no more than 2% total impurities for up to 6 hours after mixing.

[0126] In one embodiment, the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, the method comprising administering a reconstituted, dilute solution, comprising mixing component 1 and component 2 to form a reconstituted, dilute solution with an infusion medium; wherein component 1 is a room-temperature stable, dilute, parenteral preparation of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifier; and wherein, when the mixture is stored at room temperature, the reconstituted, dilute composition has no more than 1% total impurities for up to 6 hours after mixing.

[0127] In one embodiment, the invention provides a method for treating patients with recurrent or refractory multiple myeloid lesions, the method comprising administering an i.e., diluted solution of a component, comprising mixing component 1 and component 2 to form an i.e., ...

[0128] In one embodiment, the present invention provides a method for preparing an instant dilution solution of a formulation, the method comprising mixing component 1 and component 2 to form an instant dilution solution of the formulation, and then diluting the instant dilution solution of the formulation with an infusion medium; wherein component 1 comprises a room-temperature stable instant dilution parenteral preparation of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifier.

[0129] In one embodiment, the present invention provides a method for administering a reconstituted, dilute solution, the method comprising mixing component 1 and component 2 to form a reconstituted, dilute solution, and then diluting the reconstituted, dilute solution with an infusion medium; wherein component 1 comprises a room-temperature stable, dilute parenteral preparation of carfilzomib or a pharmaceutically acceptable salt thereof, and contains no more than 6% total impurities after six months of storage at 25°C and 60% relative humidity; and component 2 is an acidifier.

[0130] In one embodiment, the present invention provides a method for administering a reconstituted, dilute solution, the method comprising mixing component 1 and component 2 to form a reconstituted, dilute solution, and then diluting the reconstituted, dilute solution with an infusion medium; wherein component 1 comprises a room-temperature stable, dilute parenteral preparation of carfilzomib or a pharmaceutically acceptable salt thereof, and contains no more than 5% total impurities after six months of storage at 25°C and 60% relative humidity; and component 2 is an acidifier.

[01311] In one embodiment, the present invention provides a method for administering a reconstituted, dilute solution, the method comprising mixing component 1 and component 2 to form a reconstituted, dilute solution, and then diluting the reconstituted, dilute solution with an infusion medium; wherein component 1 comprises a room-temperature stable, dilute parenteral preparation of carfilzomib or a pharmaceutically acceptable salt thereof, and contains no more than 4% total impurities after six months of storage at 25 °C and 60% relative humidity; and component 2 is an acidifier.

[0132] In one embodiment, the present invention provides a method for administering a reconstituted, dilute solution, the method comprising mixing component 1 and component 2 to form a reconstituted, dilute solution, and then diluting the reconstituted, dilute solution with an infusion medium; wherein component 1 comprises a room-temperature stable, dilute parenteral preparation of carfilzomib or a pharmaceutically acceptable salt thereof, and contains no more than 3% total impurities after six months of storage at 25 °C and 60% relative humidity; and component 2 is an acidifier.

[0133] In one embodiment, the present invention provides a method for administering a reconstituted, dilute solution, the method comprising mixing component 1 and component 2 to form a reconstituted, dilute solution, and then diluting the reconstituted, dilute solution with an infusion medium; wherein component 1 comprises a room-temperature stable, dilute, parenteral preparation of carfilzomib or a pharmaceutically acceptable salt thereof, and contains no more than 2% total impurities after six months of storage at 25 °C and 60% relative humidity; and component 2 is an acidifier.

[0134] In one embodiment, the present invention provides a method for administering a reconstituted, dilute solution, the method comprising...The invention includes mixing components 1 and 2 to form a reconstituted, dilute solution, and then diluting the reconstituted, dilute solution with an infusion medium; wherein component 1 comprises a room-temperature stable, dilute parenteral preparation of carfilzomib or a pharmaceutically acceptable salt thereof, and when stored at 25 °C and 60% relative humidity for six months, it contains no more than 1.5% total impurities; and component 2 is an acidifier.

[0135] In one embodiment, the invention provides a method for providing a reconstituted, dilute solution, the method comprising mixing components 1 and 2 to form a reconstituted, dilute solution, and then diluting the reconstituted, dilute solution with an infusion medium; wherein component 1 comprises a room-temperature stable, dilute parenteral preparation of carfilzomib or a pharmaceutically acceptable salt thereof, and when stored at 25 °C and 60% relative humidity for six months, it contains no more than 1% total impurities; and component 2 is an acidifier.

[0136] In one embodiment, the present invention provides a method for preparing a reconstituted, dilute solution, the method comprising mixing component 1 and component 2 to form a reconstituted, dilute solution, and then diluting the reconstituted, dilute solution with an infusion medium; wherein component 1 comprises a room-temperature stable, dilute, parenteral preparation of carfilzomib or a pharmaceutically acceptable salt thereof, and contains no more than 0.5% total impurities after six hours of storage at 25 °C and 60% relative humidity; and component 2 is an acidifier.

[0137] The following examples are given for illustrative purposes and should not be construed as limiting the scope of the invention.

[0138] Example 1: Preparation of Carfilzomib Formulation Components (Batch No.) APPL-006 / 01 / 068 Carfilzomib 30 mg

[0139] Orthophosphoric acid 10 pL : Methylacetamide 500 pL Dehydrated alcohol (ethanol) 500 pL

[0140] Process:

[0141] 1. Put a portion of the carfilzomib into a container and add the carfilzomib weighed into it. Purge with bismuth 4 and distill with sodium evaporation. Mix under continuous stirring.

[0142] 2. Add the dehydrated alcohol to the solvent system and mix to obtain a clear solution.

[0143] 3. Add the weighed carfilzomib under continuous stirring and mix evenly.

[0144] 4. Make up the final volume with carfilzomib and mix thoroughly to form a homogeneous solution.

[0145] 5. The product JIJ0.22 K filter was filtered and filled into a small vial.

[0146] Example 2: Preparation of k-fezomib formulation 20 CN 121465991 A Instruction manual 18 / 30 pages

[0147]

[0148]

[0149]

[0150]

[0151]

[0152] liquid;

[0153]

[0154]

[0155]

[0156]

[0157]

[0158]

[0159]

[0160]

[0161]

[0162] Ingredients (batch) APPL-006 / 01 033 K-filzomib 10 mg rM • alcohol 425 pL Polysorbate 80 300 pL α-tocopherol 0.2 mg Lactobacillus qs ¥. pL 3-4 DMA 200 μL Process: 1. Mix propylene glycol and polysorbate 80 at 2-8°C for 10 minutes; 2. Add α-tocopherol to the above mixture; 3. Adjust the pH of the solution to 3-4 (3.5) using lactic acid; 4. Add the mixture of carfilzomib and dimethylacetamide to step 3 and mix until a clear solution is obtained; 5. Nitrogen purging and light protection are performed at 2-8°C throughout the batch preparation process; 6. The product is treated with 0.22 The pi is filtered, filled into vials, and sealed. Example 2A: Preparation of Carfilzomib Formulation Example 2A was prepared in a similar manner to Example 2. Example 2B: Preparation of Carfilzomib Formulation Example 2B was prepared in a similar manner to Example 2. Ingredients (batch number) APPL-006 01 035 Carfilzomib 10 mg [Ingredients:] ... 121465991 A Instruction Manual 19 / 30 pages

[0163]

[0164]

[0165]

[0166]

[0167]

[0168]

[0169]

[0170]

[0171]

[0172]

[0173]

[0174]

[0175]

[0176]

[0177]

[0178]

[0179] Liquid; Example 3: Carfilzomib Preparation Components (Batch A) APPL-006 01 037 Carfilzomib 10 mg Propylene Glycol Qs mL Polysorbate 80 300 pL Lactic Acid Qs pH 3-4 Methylacetamide 200 pL Water for Injection 30 mg Hydroxyphenyl 0.02 nig Components (Batch A) PPL-006.01 / 069 K filzomib 3 () mg • methylacetamide 500 uLDehydrated alcohol (ethanol) 500 pL Process: 1. Dimethylacetamide and dehydrated alcohol are mixed thoroughly at room temperature under nitrogen purging and sodium vapor lamp; 2. Carfilzomib is added to the above solvent system and mixed until completely dissolved; 3. The product is filtered through a 0.22 filter and filled into vials. Example 4: Carfilzomib Formulation Preparation Formulations T1 to T4 are prepared using a process similar to that described in Example 3. Example 5: Preparation of α-tocopherol formulation Components T1 T2 T3 T4 α-tocopherol 10 mg 30 mg 60 mg 100 mg Dimethyl ethyl amide — — 1000 pL 1000 pL Dehydrated alcohol (ethanol) 1000 pL 1000 pL ― … Components (batch number) APPL-006 01 / 062 α-tocopherol 10 mg W: alcohol 440 pL Polysorbate 80 300 pL (X-tocopherol powder 0.2 mg : methyl acetamide 250 pL Water for injection 30 pL Process: 1. Place dimethyl acetamide in a suitable container and maintain the temperature at 2-8°C; 2. Add α-tocopherol to step 1; 3. Add α-tocopherol to the DMA and tocopherol mixture from step 2 and mix thoroughly until completely dissolved; 4. Add water for injection of polysorbate 80 to step I above and mix thoroughly until a homogeneous solution is obtained. 22 CN 121465991 A Instructions for Use 20 / 30 pages

[0180]

[0181]

[0182]

[0183]

[0184]

[0185]

[0186]

[0187]

[0188]

[0189] 5. Make up the volume with propylene glycol and mix until a homogeneous solution is obtained; 6. The entire process is carried out under bismuth purging and sodium vapor lamp; 7. The product is filtered with a 0.22 filter and filled into vials. Example 5A: Example 5A is prepared in a similar manner to Example 5. Example 5B: Example 5B is prepared in a similar manner to Example 5. Ingredient (batch number) APPL-006 / 01 / 058 Pir•Zomi 30 mg Polysorbate 80 300 pL a-Fertility® 0.2 mg lactate Qs i'. pH 3-4: Methionamide 250 pL, Water for Injection 30 mg, Superconducting PG Qs 1 mL Table 1: Stability components of the formulations prepared in Examples 5A and 5B (batch 4) APPL-006 / 01 ()59 P filzomib 10 mg, Polysorbate® 80 300 pL, a•tocopherol 0.2 mg, HCl Qs i': pH 3-4, DMA 250 pL, Water for Injection 30 mg, Superconducting PG Qs 1 mL 23CN 121465991 A Specification 21 / 30 pages

[0190]

[0191]

[0192]

[0193]

[0194]

[0195]

[0196]

[0197]

[0198]

[0199]

[0200]

[0201] Example 6: Preparation of Carfilzomib Formulation The formulation of this example was prepared by a process similar to that described in Example 5. Batch No. APPL-006 / 01 / 058 APPL-006 01 / 059 _Test Parameters* Inch Point Cut-off 2-8°C Day- RT 7 K 2-8°C 7 Initial 2-8 3 RT 7 , Description Clear Drop Colorless Solution Solution Clear Drop Solution Clear Drop Solution Liquid Related Substances NMT 0.2% ND 0.02 0.22 0.01 ND ND ().05 Impurities NMT 0.2% ND ND ND ND ND ND ND Chlorine Impurities NMT 0.5% ND ND ND ND ND 0.09 ND Alcohol Impurities NMT 0.5% ND ().02 0.18 0.02 0.01 0.01 0.06 Furnace Enantiomer Impurities NMT 0.2% ND ND ND ND ND ND ND Section. Oxide impurities NMT 1.0% 0.02 0.02 0.11 0.02 0.02 0.02 0.02 Any other individual impurities NMT ().2 % 0.06 0.06 0.36 0.02 0.06 ().06 0.39 4.41 Total impurities NMT 3.0% 0.08 0.22 2.IX ().23 0.09 ().32 Example 6A: Carfilzomib preparation ingredients (batch) APPL-006 / 01 / 070 Carfilzomib 15 mg : Alcohol 22 () pL Polysorbate 80 210 pL α-Oxygen 0.2 mg : Methylacetamide 275 pL Dehydroethanol (ethanol) 275 pL Ingredients (batch g) APPL-006 / 01 / 078 Mizomib 30 mg 0.5 nig Dehydroalcohol (ethanol) Qs ¥. 1 mL 1. Add sufficient ethanol B to the manufacturing container; 2. Add the weighed α-tocopherol while continuously stirring until a homogeneous solution is obtained, and record this description; 3. Add the weighed carfilzomib while continuously stirring until a homogeneous solution is obtained, and record this description; 4. Make up the final volume with ethanol and stir until a homogeneous solution is obtained; 5. Filter the bulk through a 0.22 g PTFE filter and fill into vials. Example 6B: Preparation of Carfilzomib Formulation 24 CN 121465991A Specification Page 22 of 30 Ingredients (Batch No.) APPL-006 / 0I 087 Carfilzomib 30 mg α-tocopherol 0.5 mg N-methylacetamide 200 mL Dehydrated alcohol (ethanol) Qs Ad 1 mL.

[0203] 1. Place a sufficient amount of N,N-dimethylacetamide into a manufacturing container;

[0204] 2. Add the weighed α-tocopherol under continuous stirring until a homogeneous solution is obtained, and record this description;

[0205] 3. Add the weighed carfilzomib under continuous stirring until a homogeneous solution is obtained, and record this description;

[0206] 4. Add ethanol to adjust to the final volume, and stir until a homogeneous solution is obtained;

[0207] 5. Filter the bulk through a 0.22 μm PTFE filter and fill it into vials.

[0208] Example 7:

[0209] Table 2: Comparison of stability of preparations prepared in Examples 1, 2, 3 and 5 Batch No. APPL- 006 / 01 / 033 APPL- 006 / 01 / 033 APPL- 006 / 01 / 062 APPL- 006 / 01 / 062 APPL- 006 / 01 / 068 APPL- 006 01 / 068 APPL- 006 01 069 APPL- 006 01 069 Test parameter ◆ Time point RT Initial 0° C RT 21 days RT Initial 0° C RT 35 days RT Initial 0° C RT After 24 days RT Initial 0° C RT After 24 days Description Clear, colorless solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Clear solution Related substances General impurity NMT 0.2% ND 0.12 ND ND ND ND ND ND Terminal impurity NMT 0.2% ND ND ND ND ND ND ND ND Chlorine impurity NMT 0.5% ND ND ND ND ND 0.09 ND ND Glycol impurity NMT 0.5% ND 0.16 ND 0.15 0.01 1.9 0.01 ND Diastereomeric impurity NMT 0.2% ND ND ND ND ND ND ND 0.01 Epoxide impurity NMT 1.0% ND 1.23 0.02 0.03 0.02 0.88 0.01 0.01 Any other individual impurity NMT 0.2% ND 0.15 0.06 0.13 0.07 2.19 0.06 0.06 Total impurity NMT 3.0% ND 2.5 0.08 0.75 0.16 7.31 0.130.19

[0211] *RT indicates room temperature (stability test parameters: temperature 25 °C and relative humidity 60%), *ND indicates not detected, *NMT indicates not exceeding.

[0212] Example 8: Preparation and stability data of injectable compositions with acidifiers. 25 CN 121465991 A Instruction Manual 23 / 30 pages

[0213]

[0214]

[0215]

[0216] ■ .. . ... . . . Ingredients Qty / ml Carfilzomib 30 mg α-Tocopherol 0.5 mg Phosphoric acid 15 pL Dehydrated ethanol qs to 1 mL Procedure: 1. Place 80% of the required dehydrated ethanol in a clean container; 2. Add the required amount of carfilzomib to the solvent in step 1 at 2-8°C and dissolve it with a mechanical stirrer until a clear solution is observed;

[0217] 3. Add the required amount of α-Tocopherol at 2-8°C with stirring in step 2 until a clear solution is observed;

[0218] 4. Add the required amount of α-Phosphoric acid at 2-8°C with stirring in step 3 until a clear solution is observed;

[0219] 5. Prepare the final batch size with the desired amount of dimethylacetamide and mix it thoroughly at 2-8°C;

[0220] 6. Filter the bulk solution using a 0.2-micron PTFE filter;

[0221] 7. Fill into amber vials, cover with nitrogen and seal properly with rubber stoppers;

[0222] 8. The vials maintain thermal stability at 25°C and 60%RH and 2-8°C.

[0223] Table 3: Stability data of injectable compositions with acidifiers Storage conditions 25°C / 60% RH 2-8°C Sample conditions Initial 15 days IM IM Description Compliant Compliant Compliant Compliant P Specimen determination 99.9% 94.0% 89.0% 98.7% Related substances Acid impurities ND 0.16% 0.45% ND (unidentified) 0.29% β-Impuric impurities 0.01% 1.43% α-Alcohol impurities ND 0.13% 0.00 0.03% Enantiomer impurities ND ND ND ND ND Specimen impurities 0.02% 0.20% 0.51% 0.05% Any other individual impurities not detected 1.02% 1.34% 0.43% Total impurities 0.06% 5.37% 8.59% 1.34%

[0225] Example 9: Preparation of injectable composition and stability data before and after mixing with acidifier Component Qty / ml k Fezomib 30 mg : Methylacetamide 500 pL Dehydrating agent (ethanol) 500 pL

[0227] Procedure:

[0228] 1. Place 80% of the desired amount of dimethylacetamide H in a clean container;

[0229] 2. At 2-8°C, add the desired amount of carfilzomib from step 1 and dissolve it with a mechanical stirrer until a clear solution is observed; 26 CN 121465991 A Specification 24 / 30 pages

[0230] 3. At 2-8°C, add the desired amount of dehydrated ethanol with stirring from step 2 until a clear solution is observed;

[0231] 4. Prepare the desired amount of dimethylacetamide to the final batch size and mix it thoroughly at 2-8°C;

[0232] 5. Filter the bulk solution through a 0.2-micron PTFE filter;

[0233] 6. Fill into an amber vial, cover with bismuth gas and seal it properly with a rubber stopper;

[0234] 7. The vial maintains thermal stability at 25°C / 60%RH and 2-8°C.

[0235] Table 4: Stability data of injectable compounds before mixing with acidifier Initial 25°C 60 RH 1M 25°C 60 RH 2M 25°C 60 RH 3M 2-8°C 1M 2-8°C 2M 2^(. 3M Description Clarifying solution Clarifying solution Clarifying solution Clarifying solution Clarifying solution Clarifying solution pH K.4 NP NP 1 NP NP NP NP Carfilzomib determination 100.1% 100.5% 101.10% 99.2% 100.1% 101.40% 103.1% Paired substances • Alcoholic acid ND ().02% 0.03% 0.04% 0.01% 0.02% MMft Impurities ().01% 0.02% 0.03% 0.04% ().01% 0.02% o.oz、: i Any other individual impurities ND 0.09% 0.1% ().13% ().05% 0.05% 0.05% Total impurities 0.10% ().30% 0.49% 0.46% 0.1 X% 0.22% ().21% *NP=Not performed

[0237] and 5: The process of mixing acidifier into dilute the composition: Product vial (via 1) Vial (via 2) Vial 1 Vial 2 Final concentration 30 mg / mL Example 2 Product 90 μL OPA to 1 mL water for injection, USP 1 mL 0.5 mL 20 mg / mL aszomib

[0239] 1. Aseptically mix vial 1 and vial 2 according to Table 3 above;

[0240] 2. Gently rotate and / or slowly pour S from the vial for about 1 minute;

[0241] 3. Visually inspect for particulate matter and discoloration before mixing; the diluted product should be a clear, colorless solution.If any discoloration or particulate matter is observed, mixing shall not be performed;

[0242] 4. Dilute the mixed product solution from step 3 with sterile water for injection to concentrations of 0.5 mg / mL and 1.5 mg / mL, and conduct solution stability testing at 25 °C and 2 - 8 °C.

[0243] Table 6: Stability data of injectable composition after mixing with acidifying agent (concentrations of 0.5 mg / mL and 1.5 mg / mL) 27 CN 121465991 A Description Page 25 / 30

[0244]

[0245]

[0246]

[0247]

[0248]

[0249]

[0250]

[0251]

[0252]

[0253]

[0254]

[0255]

[0256]

[0257] Example 10: Preparation of injectable composition and stability data before and after mixing with acidifying agent 0.5 mg mL 1.5 mg mL Test parameter Initial 25°C / 24Hr 2-8°C 24Hr Initial 25°C / 24Hr 2-8°C 24Hr Description Compliant Compliant Compliant Compliant Compliant Compliant pH 2.21 2.48 2.40 2.10 2.27 2.45 Osmolality (mOsm / kg) 259 259 258 795 776 776 Light transmittance% 98.929 99.449 99.541 98.944 98.369 98.926 Absorbance 0.007 0.006 0.007 0.012 0.013 0.014 Carfilzomib assay 97.1% 98.4% 98.6% 99.40% 99.7% 98.9% Methanol impurity 0.12% 0.16% 0.18% 0.16% 0.16% 0.21% Any other individual impurity 0.06% 0.09% 0.13% 0.09% 0.10% 0.13% Total impurity 0.41% 0.42% 0.56% 0.44% 0.51% 0.70%...... Component Qty / ml Carfilzomib 6.0 mg Process: 1. Place 80% of the required amount of dimethylacetamide in a clean container; 2. Add the required amount of carfilzomib to step 1 at 2-8°C and dissolve it with a mechanical stirrer; 3. Prepare to the final batch specification with the required amount of dimethylacetamide and mix it thoroughly at 2-8°C; 4. Filter the bulk solution using a 0.2 micron PTFE filter; 5. Fill into amber vials, then blanket with nitrogen and seal properly with a rubber stopper; 6. Store the vials at 25 °C / 60%RH, 2 - 8 °C and 40It maintains thermal stability at °C / 75%RH. Table 7: Stability data of injectable compositions before mixing with acidifier *ND=Not detected Table 8: Process of mixing acidifier into dilute composition Initial 25°C 60 RH 15 25°C / 60 RH 3M 2-8°C / 3M 40°C / 75 RH 15 / < 40°C RH 1M Description Conforms ... 0.07% 0.07% 0.06% 0.04° <. 0.07% 0.09% Total impurities 0.13% 0.23% 0.29% 0.18?^ 0.18% 0.35% 0.46% i 28 CN 121465991 A Instructions for Use 26 / 30 pages Product vial (via 1) Selected vial (via 1) Volume of vial 1 Volume of vial 2 Final concentration of API 60 mg inL Example 3 Product 9 () μL OPA. in (50:50 water for injection, USP and dehydrated ethanol) 1 mL 0.5 mL 40 mg / mL

[0259] 1. Aseptically mix vial 1 and vial 2 according to the table above;

[0260] 2. Gently rotate and / or slowly pour H over the vial for about 1 minute;

[0261] 3. Visually inspect for particulate matter and discoloration before mixing; the diluted product should be a clear, colorless solution. If any discoloration or particulate matter is observed, it should not be mixed with the infusion agent;

[0262] 4. Dilute the mixed product solution with sterile water for injection to concentrations of 0.5 mg / mL and 1.5 mg / mL, and test the solution stability at 25°C and 2-8°C.

[0263] Table 9: Stability data of injectable compositions after mixing with acidifiers (concentrations of 0.5 mg / mL and 1.5 mg / mL) 0.5 mg / mL 1.5 mg / mL Test parameters Initial 25°C / 4Hr 2-8°C / 24Hr Initial 25°C 4Hr 2-8°C 24Hr Description Compliance Compliance pH 2.48 2.46 2.49 2.39 2.32 Pantone concentration (msOrn / kg) 135 136 136 387 3K5 389 Transmittance %99.132 99.397 99.6X4 9X.6X0 99.109 99.214 Absorbance 0.005 0.008 0.006 0.013 0.01() 0.01() k (as determined by Zyrometer) 96.80% 95.6% 95.8% 90.30% 89.7% 90.5"o : . Calcium 0.11% 0.15°o 0.16% 0.13% 0.13% 0.16% Any other ¥ at most 0.12% 0.09% 0.10% 0.12% 0.13% 0.10°o Total residual mass 0.36% 0.37% 0.45% 0.44% 0.46% 0.53%

[0265] Example 11: Preparation of Carfilzomib Formulation Components (Batch APPL-006 / 01 / 062 Carfilzomib 10 mg NN DMA 250 mg Polystyrene 80 300 pL α-Tocopherol 0.2 mg Water for Injection 30 mg Ultrapure Liquor Qs 1 mL

[0267] Process:

[0268] 1. Place a standard amount of N,N-dimethyl ethylamide in a manufacturing container at a temperature of 2-8°C;

[0269] 2. Add the weighed batch amount of α-tocopherol under continuous stirring until a homogeneous solution is obtained;

[0270] 3. Add the weighed batch amount of α-tocopherol under continuous stirring until completely dissolved;

[0271] 4. Add the weighed batch amount of water for injection under continuous stirring until a homogeneous solution is obtained;

[0272] 5. While stirring, add the weighed batch amount of polysorbate 80 until a homogeneous solution is obtained; 29 CN 121465991 A Instruction manual 27 / 30 pages

[0273]

[0274]

[0275]

[0276]

[0277]

[0278]

[0279]

[0280]

[0281]

[0282]

[0283]

[0284]

[0285]

[0286]

[0287]

[0288]

[0289]

[0290]

[0291]

[0292]

[0293]

[0294]

[0295]

[0296] 6. Make up the final volume with super-viscous PG and stir until a homogeneous solution is obtained; 7. Filter the bulk through a 0.22 PTFE filter and fill into vials. Example 12: Carfilzomib Formulation Preparation Components (Batch Number) APPL-006 01 / 063 Carfilzomib 10 mg Polysorbate 80 300 pL a-1 0.2 mg Ethanol (dehydrated alcohol) 500 Water for Injection 30 mg Ultrapure Propanol Qs to 1 mL Procedure: 1.1. Add a standard amount of ethanol H to the manufacturing container at a temperature of 2-8°C; 2. Add a weighed batch amount of α-tocopherol under continuous stirring until a homogeneous solution is obtained; 3. Add a weighed batch amount of carfilzomib under continuous stirring until completely dissolved; 4. Add a weighed batch amount of water for injection under continuous stirring until a homogeneous solution is obtained; 5. Add a weighed batch amount of polysorbate 80 under continuous stirring until a homogeneous solution is obtained; 6. Make up the final volume with ultrapure PG and stir until a homogeneous solution is obtained; 7. Filter the bulk through a 0.22 PTFE filter and fill into vials. Example 13: Preparation of Carfilzomib Formulation Ingredients (Batch No.) APPL-006 01 066C Carfilzomib 10 mg Polysorbate 80 300 mg α-Tocopherol 0.2 mg Orthophosphoric Acid (OPA) QS to pH 5-6 Dimethylacetamide 250 mg Water for Injection 30 mg Ultrapure Propanol QS 1 mL Procedure: 1. Add standard M dimethylacetamide H to a manufacturing vessel at a temperature of 2-8°C; 2. Add the weighed batch of α-tocopherol under continuous stirring until a homogeneous solution is obtained; 3. Add the weighed batch of polysorbate 80 under continuous stirring until completely dissolved; 4. Add the weighed batch of water for injection under continuous stirring until a homogeneous solution is obtained; 5. Add the weighed batch of ultrapure PG under continuous stirring until a homogeneous solution is obtained; 6. 7. Add the weighed batch amount of carfilzomib under continuous stirring until a homogeneous solution is obtained; 8. Make up the final volume with ultrapure PG and stir until a homogeneous solution is obtained; 9. Filter the bulk through a 0.22 PTFE filter and fill it into vials. Example 14: Preparation of Carfilzomib Formulation 30 CN 121465991 A Instruction Manual 28 / 30 pages

[0297]

[0298]

[0299]

[0300]

[0301]

[0302]

[0303]

[0304]

[0305]

[0306]

[0307]

[0308]

[0309]

[0310]

[0311]

[0312]

[0313]

[0314]

[0315]

[0316]

[0317]

[0318]

[0319]

[0320]

[0321] Ingredients (Batch No.) APPL-006 / 01 067 Carfilzomib 10 mg Polysorbate 80 300 mg α-Tocopherol 0.2 mg OPA QS pH 5-6 Water for Injection 30 mg, ethanol QS 1 mL, ethanol 4"O ing process: 1. Add the standard amount of ethanol to the manufacturing container at a temperature of 2-8°C;2. Add the weighed batch amount of α-tocopherol under continuous stirring until a homogeneous solution is obtained; 3. Add the weighed batch amount of polysorbate 80 under continuous stirring until completely dissolved; 4. Add the weighed batch amount of water for injection under continuous stirring until a homogeneous solution is obtained; 5. Add the weighed batch amount of ultrapure PG under continuous stirring until a homogeneous solution is obtained; 6. Add the weighed batch amount of carfilzomib under continuous stirring until a homogeneous solution is obtained; 7. Make up the final volume with ultrapure PG and stir until a homogeneous solution is obtained; 8. Filter the bulk through a 0.22 M PTFE filter and fill into vials. Example 15: Preparation of Carfilzomib Formulation (Batch 4) APPl -()06 ()! 102 P *Carfilzomib 6() mg N,N-DMA QS 1 mL Procedure: 1. Place 90% N,N-dimethylacetamide in a manufacturing container at 2-8°C; 2. Add the weighed carfilzomib of batch S under continuous stirring until a homogeneous solution is obtained; 3. Add N,N-dimethylacetamide to the final volume and stir until a homogeneous solution is obtained; 4. Filter the bulk through a 0.22 g PTFE filter and fill into vials. Example 16: Preparation of Carfilzomib Formulation Ingredients (Batch 5) APPL-006.01 103 l < Carfilzomib 30 mg NN DMA 500 pL Ethanol QS: 1 ml. Procedure: 1. Weigh the batch amount of N,N-dimethylacetamide H into the manufacturing container at 2-8°C; 2. Add the batch amount of carfilzomib under continuous stirring until a homogeneous solution is obtained; 3. Make up the final volume with ethanol and stir until a homogeneous solution is obtained; 4. Filter the bulk through a 0.22 g PTFE filter and fill into vials. Example 17: Preparation of Carfilzomib Formulation 31 CN 121465991 A Instruction Manual 29 / 30 pages

[0322]

[0323]

[0324]

[0325]

[0326]

[0327]

[0328]

[0329]

[0330]

[0331]

[0332]

[0333]

[0334]

[0335]

[0336]

[0337]

[0338] Batch Specification: 50 mL Batch No. APPL-OO6.OI-JO5 Composition m* (mg / mL) Mzomib 60.0 N,N-methylacetamide QS±mL Process: 1. Place 80% N,N-dimethylacetamide in a manufacturing container at a temperature of 2-8°C; 2. Add the weighed batch W: of carfilzomib under continuous stirring until a homogeneous solution is obtained; 3.RIN, N-dimethylacetamide to make up the final volume, stir until a homogeneous solution is obtained; 4. Filter the wood through a 0.22 PTFE filter (fill into a vial). Table 10: Thermal stability of APPL-006 / 01 / 105 + 4:. Analysis results NMT: not more than, ND- not detected Example 18: Carfilzomib preparation time point Initial 40±2°C / 75±5%RH 25±2°C (76 (l ±5%RH) Conditions IM 2M 3M Description Along the solution® clear solution Along the solution Along the solution Along the solution Along the solution Carfilzomib determination 101.2% 100.5% NA 102.5% 101.4% Related substances General impurities ND ND ND ND ND ND ND Fiber* ND 0.02% ND ND ND : Alcohol impurities ND ND ND ND ND Diasteremeric impurities ND ND ND ND ND MMft impurities ND 0.06% 0.07% 0.11% ND Maximum individual nonspecificity 0.04% 0.15% 0.07% 0.11% 0.05% Total impurities 0.07% 0.38% 0.32% 0.36% ().11% Batch specification: 50 mL Batch 4 APPL-006 / 01 / 106 Ingredients / ii h* (mg. mL) Carfilzomid 30.0 N,N-: A methyl ethyl ether QS: mL ___________________________ 500.0 pL Process: 1. Weigh the batch amount of N,N-dimethylacetamide g into the manufacturing container at a temperature of 2-8°C; 2. Add the weighed batch amount of carfilzomid under continuous stirring until a homogeneous solution is obtained; 3. Make up the final volume with ethanol and stir until a homogeneous solution is obtained; 4. Pass through 0.22 The PTFE filter body is filtered and filled into a vial. Table 11: Thermal stability and analysis results of APPL-006 / 01 / 106 32 CN 121465991 A Instruction manual 30 / 30 pages

[0339]

[0340] NMT: not exceeding, ND - not detected at the initial 40±2°C / 75±5% RH 25±2° (7 60 ±5% RH) Conditions IM 2M 3M 3M Description Clarification solution quenching solution clarification solution clarification solution tablets 105.8% 103.5% NA 102.6°0 102.6% Related substances Acid impurities ND ND ND 0.03% ND Chlorine impurities 0.01% 0.11% 0.05% 0.23% 0.04° <) 'Impurity impurities ND ND 0.14% 0.22% ND II: Enantiomer ImpuritiesND ND ND ND ND Vaporized substances 0.01% 0.01% 0.05% 0.21% 0.05% Highest individual nonspecific impurities 0.06% 0.1X% 0.24% 0.4X% 0.1% 0.13% 1.05% 1.55°u 2.40% 0.19% 33 Our Ref: 26HKI028-101 Summary of Specification Invention Title: Stable, Immediately Diluted Formulation of Carfilzomib This invention provides a room-temperature stable, immediately dilute, injectable formulation comprising carfilzomib or a pharmaceutically acceptable derivative thereof. This invention also provides a method of treating patients with multiple myeloma by administering a room-temperature stable, immediately dilute, injectable formulation comprising carfilzomib or a pharmaceutically acceptable derivative thereof. ABSTRACT Title of Invention : STABLE READY TO DILUTE FORMULATIONS OF CARFILZOMIB The invention provides methods for treating patients with multiple myeloma by administering room temperature stable ready to dilute injectable formulations comprising carfilzomib or its pharmaceutically acceptable derivatives. Abstract

Claims

1. A room temperature stable ready-to-dilute injectable formulation comprising carfilzomib or a pharmaceutically acceptable derivative thereof and one or more solvents selected from isopropyl alcohol, benzyl alcohol, glycerol, dimethylacetamide, N-methylpyrrolidone, dimethylsulfoxide (DMSO), diethylene glycol monoethyl ether, caprylocaproyl polyoxyl-8 glycerides, tetrahydrofuran polyethylene glycol ether or mixtures thereof; wherein, The formulation contains no more than 6% total impurities when stored for at least three months.

2. The room temperature stable ready-to-dilute injectable formulation according to claim 1, wherein, The concentration of carfilzomib or its pharmaceutically acceptable derivatives is in the range of about 10 mg / mL to about 100 mg / mL.

3. The room temperature stable ready-to-dilute injectable formulation according to claim 1 or 2, wherein, The concentration of carfilzomib or its pharmaceutically acceptable derivatives is in the range of about 10 mg / mL to about 60 mg / mL.

4. The room-temperature stable, dilution-type injectable formulation according to claim 1 or 2, further comprising one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants.

5. The room temperature stable ready-to-dilute injectable formulation according to claim 1 or 2, wherein, The appropriate ratio (w / w) of the solvent to carfilzomib or its pharmaceutically acceptable derivative is about 100:1 to 8:

1.

6. The room temperature stable ready-to-dilute injectable formulation according to claim 4, wherein, The antioxidants are selected from butylated hydroxytoluene, butylated hydroxyanisole, propyl gallate, C.-tocopherol, DL-tocopherol, C.-tocopherol acetate, C.-tocopherol polyethylene glycol succinate (vitamin E TPGS), L-cysteine, ascorbyl palmitate thioglycolic acid, sodium metabisulfite (SMBS), ascorbic acid, sodium formaldehyde sulfoxylate, sodium EDTA, and thioglycerol.

7. The room-temperature stable, dilution-type injectable formulation according to claim 6, wherein, The antioxidant is present at a concentration of about 0.005% to about 5% by weight of the total composition.

8. The room-temperature stable, dilution-type injectable formulation according to claim 1 or 2, wherein, The formulation is stored at 25°C and 60% relative humidity or at 40°C and 75% relative humidity.

9. The room-temperature stable, dilution-type injectable formulation according to claim 1 or 2, wherein, The formulation contains no more than 5%, no more than 4%, no more than 3%, no more than 2%, no more than 1.5%, no more than 1%, or no more than 0.5% total impurities after the expiration of the storage period.

10. A method for treating a patient with relapsed or refractory multiple myeloma, the method comprising administering a room-temperature stable, dilution-compatible injectable formulation of one or more solvents, carfilzomib preparations, or pharmaceutically acceptable derivatives thereof; wherein, The formulation contains no more than 6% total impurities when stored for at least six months.

11. The method of treating a patient with relapsed or refractory multiple myeloma according to claim 10, wherein, The dilution-type injectable formulation is stable when stored for at least six months.

12. A method of administering a reconstituted, dilute formulation, the method comprising mixing component 1 and component 2 to form the reconstituted, dilute formulation using an infusion medium; wherein, Component 1 comprises a room-temperature stable, i.e., diluted formulation of carfilzomib or a pharmaceutically acceptable derivative thereof, and contains no more than 6% total impurities after storage for at least three months; and component 2 is an acidifier.

13. The method of administering a reconstituted, i.e., diluted formulation according to claim 12, wherein, The concentrations of components 1 and 2 are in the range of about 10 mg / mL to about 60 mg / mL.

14. The method of administering a reconstituted, i.e., diluted formulation according to claim 12 or 13, wherein, The appropriate ratio (w / w) of the acidifier to carfilzomib or a pharmaceutically acceptable derivative thereof is selected from about 1:50 to about 1:

1.

15. The method of administering a reconstituted, i.e., diluted formulation according to claim 12 or 13, wherein, Component 1 shall be stored at 25°C and 60% relative humidity or at 40°C and 75% relative humidity for at least three months.

16. The method of administering a reconstituted, i.e., diluted formulation according to claim 12 or 13, wherein, Component 1 comprises a room-temperature stable, i.e., diluted formulation of carfilzomib or a pharmaceutically acceptable derivative thereof, and contains no more than 6% total impurities when stored for at least six months.

17. The method of administering a reconstituted, i.e., diluted formulation according to claim 12 or 13, wherein, Component 1 contains no more than 5%, no more than 4%, no more than 3%, no more than 2%, no more than 1.5%, no more than 1%, or no more than 0.5% total impurities after the storage period expires.

18. The method of administering a reconstituted, i.e., diluted formulation according to claim 12 or 13, wherein, The acidifying agent is selected from citric acid, acetic acid, maleic acid, phosphoric acid, succinic acid, tartaric acid, ascorbic acid, benzenesulfonic acid, oxalic acid, fumaric acid, orthophosphoric acid, gluconic acid, malic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, galacturonic acid, lactic acid, lacturonic acid, edetic acid, gentian acid, metaphosphoric acid, nitric acid, penti acid, glycolic acid, or mixtures thereof.

19. A method for treating a patient with relapsed or refractory multiple myeloma, the method comprising administering a reconstituted, i.e., diluted formulation, comprising mixing component 1 and component 2 to form the reconstituted, i.e., diluted formulation with an infusion medium; wherein, Component 1 is a room-temperature stable, dilute parenteral formulation of carfilzomib or a pharmaceutically acceptable derivative thereof, component 2 is an acidifier, and wherein, when the mixture is stored at room temperature, the reconstituted dilute composition contains no more than 2% total impurities for up to 6 hours after mixing.

20. The method of treating a patient with relapsed or refractory multiple myeloma according to claim 19, wherein, When the mixture is stored at room temperature, the reconstituted i.e. diluted composition contains no more than 1% total impurities for up to 6 hours after mixing, no more than 2% total impurities for up to 5 hours after mixing, no more than 1% total impurities for up to 5 hours after mixing, no more than 2% total impurities for up to 4 hours after mixing, or no more than 1% total impurities for up to 4 hours after mixing.